# HARMONi-7 (ivonescimab): what clinicians are saying

> 109 statements from 43 sources (1 podcast, 1 video, 41 posts), 41 of them from 11 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026.

## Report

- Trial: A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
- NCT ID: NCT06767514
- Registry: https://clinicaltrials.gov/study/NCT06767514
- Sponsor: Summit Therapeutics
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: ivonescimab
- Indication: first-line metastatic NSCLC with high PD-L1 expression
- Version: v1.0.0, edition 1
- Accepted: 2026-11-19 UTC
- Last checked: 2026-11-19 UTC
- Release hash: 9bc7431a57813b033e040c199a754f97e897c8191e14b51ab21c7d57b9af7291

## Counts

- Commentary sources screened: 67
- Sources cited by verified statements: 43
- Verified statements: 109
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 41
- Findings: 13
- Named people in screened sources (unnamed speakers and accounts not counted): 27
- Speakers cited: 26
- Cited speakers with a verified identity: 15
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 11
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 11
- By role and specialty (the abstract's specialty counts):
  - 9 physician, Medical oncology
  - 1 physician, specialty not confirmed
  - 1 physician, Pathology
- Organisational or shared accounts (not counted as people): 11

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

For HARMONi-7, the clinicians cited find support in HARMONi-2’s PD-L1-high survival findings, but stop short of endorsing worldwide treatment change. One medical oncologist considers added VEGF toxicity manageable with patient selection; another cites it among reasons for caution. Discussion of the trial itself is limited; earlier ivonescimab evidence supplies context rather than its outcomes. The cautious readings call for fuller disclosure and confirmation beyond China.

## Question clinicians left open

What do clinicians need HARMONi-7 to show about overall survival and VEGF-related toxicity before replacing pembrolizumab with ivonescimab as first-line monotherapy for PD-L1-high metastatic NSCLC globally?

From finding F1 (22 statements from 6 speakers in 7 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. HARMONi-2 PD-L1-high OS: what speakers say
  - 22 statements from 6 speakers in 7 sources, 1 of them a podcast or video.
  - 5 of the report's 11 cited clinicians.
- F3. PD-L1: what speakers say
  - 9 statements from 7 speakers in 7 sources, 1 of them a podcast or video.
  - 4 of the report's 11 cited clinicians.
- F4. Censoring: speakers question it; one queries non-toxicity-coded stops
  - 4 statements from 2 speakers in 2 sources.
  - 2 of the 2 named speakers in this finding hold this view; 1 of them holds its caveat, “one queries non-toxicity-coded stops”.
  - 1 of the report's 11 cited clinicians.
- F5. TROP2 ADC combinations: where speakers split on cross-trial trade-offs
  - 5 statements from 2 speakers in 2 sources.
  - 2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other.
  - No named clinician · accounts and unnamed speakers.
- F6. First-line VEGF: why a speaker worries it could limit TIL eligibility
  - 3 statements from 2 speakers in 1 source.
  - 1 of the 2 named speakers in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.
- F7. Global validation: some speakers await it; some weigh regional enrollment
  - 15 statements from 10 speakers in 12 sources, 2 of them podcasts or videos.
  - 5 of the 10 named speakers in this finding hold this view; 2 of the 10 hold its caveat, “some weigh regional enrollment”.
  - 6 of the report's 11 cited clinicians.
- F8. Ivonescimab in China: why a speaker sees a tentative case for use now
  - 1 statement from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F2. VEGF toxicity: where speakers split on manageability and added risk
  - 10 statements from 4 speakers in 4 sources, 1 of them a podcast or video.
  - 4 of the 4 named speakers in this finding take a side on this question: 2 on one side, 3 on the other, 1 on both.
  - 2 of the report's 11 cited clinicians.
- F9. TIL–ivonescimab: a speaker would explore it if PD-1/VEGF became standard
  - 2 statements from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.
- F10. HARMONi-6: a speaker expects significant OS benefit from PFS gains, awaiting OS data
  - 12 statements from 2 speakers in 4 sources, 2 of them podcasts or videos.
  - 1 of the 2 named speakers in this finding holds this view; 1 of them holds its caveat, “awaiting OS data”.
  - 1 of the report's 11 cited clinicians.
- F11. Investing: speakers await OS or global data; one differs on FDA impact
  - 10 statements from 2 speakers in 5 sources.
  - 2 of the 2 named speakers in this finding hold this view; 1 of the 2 holds its caveat, “one differs on FDA impact”.
  - No named clinician · accounts and unnamed speakers.
- F_context_C95. Ivonescimab overview: a clinician welcomes it and awaits HARMONi-6 OS
  - 1 statement from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “await HARMONi-6 OS”.
  - 1 of the report's 11 cited clinicians.
- F_H6_expectations. HARMONi-6: a speaker expects significant OS gain and floats a safety learning curve
  - 4 statements from 2 speakers in 2 sources, 1 of them a podcast or video.
  - 1 of the 2 named speakers in this finding holds this view; 1 of them holds its caveat, “float a safety learning curve”.
  - 1 of the report's 11 cited clinicians.

6 of the 13 findings and 30 of the 109 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 22 | 13 | 7 | 6 | 3 |
| F3 | 9 | 9 | 7 | 7 | 4 |
| F4 | 4 | 4 | 2 | 2 | 3 |
| F5 | 5 | 3 | 2 | 2 | 3 |
| F6 | 3 | 2 | 1 | 2 | 3 |
| F7 | 15 | 13 | 12 | 10 | 3 |
| F8 | 1 | 1 | 1 | 1 | 2 |
| F2 | 10 | 6 | 4 | 4 | 3 |
| F9 | 2 | 1 | 1 | 1 | 3 |
| F10 | 12 | 8 | 4 | 2 | 5 |
| F11 | 10 | 7 | 5 | 2 | 3 |
| F_context_C95 | 1 | 1 | 1 | 1 | 2 |
| F_H6_expectations | 4 | 3 | 2 | 2 | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 11 | 4 | 0 | 0 | 7 | 23 | 0 | 6 posts and articles, 1 podcast or video |
| F3 | 5 | 1 | 0 | 2 | 1 | 10 | 0 | 6 posts and articles, 1 podcast or video |
| F4 | 1 | 3 | 0 | 0 | 0 | 4 | 1 | 2 posts and articles |
| F5 | 2 | 0 | 0 | 3 | 0 | 5 | 0 | 2 posts and articles |
| F6 | 3 | 0 | 0 | 0 | 0 | 3 | 1 | 1 post or article |
| F7 | 11 | 2 | 0 | 0 | 2 | 15 | 0 | 10 posts and articles, 2 podcasts and video |
| F8 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 post or article |
| F2 | 7 | 0 | 0 | 2 | 1 | 11 | 1 | 3 posts and articles, 1 podcast or video |
| F9 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 1 post or article |
| F10 | 5 | 3 | 0 | 0 | 4 | 13 | 1 | 2 posts and articles, 2 podcasts and video |
| F11 | 7 | 1 | 0 | 0 | 2 | 10 | 0 | 5 posts and articles |
| F_context_C95 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 post or article |
| F_H6_expectations | 0 | 0 | 0 | 0 | 4 | 5 | 0 | 1 post or article, 1 podcast or video |

### Trial dimensions

- Primary endpoint: Overall Survival (OS): F1 (11 shared claims), F3 (1 shared claims), F7 (2 shared claims)
- Primary endpoint: Progression free survival (PFS): F1 (3 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (1 shared claims), F7 (1 shared claims)
- Secondary endpoint: Objective response rate (ORR): F1 (1 shared claims)
- Secondary endpoint: Disease control rate ( DCR): no finding draws on it directly
- Secondary endpoint: Duration of response (DoR): no finding draws on it directly
- Secondary endpoint: Adverse Events (AE): incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results: F1 (1 shared claims), F6 (1 shared claims), F7 (1 shared claims)
- Population and setting: F1 (5 shared claims), F3 (4 shared claims), F7 (2 shared claims)
- The comparison: F1 (3 shared claims), F3 (8 shared claims), F5 (5 shared claims), F8 (1 shared claims)
- Safety and tolerability: F1 (1 shared claims), F6 (2 shared claims), F7 (1 shared claims)
- Design and conduct: F1 (1 shared claims), F3 (1 shared claims), F4 (1 shared claims), F7 (3 shared claims)

## Abbreviations

- ADC: antibody–drug conjugate
- AE: adverse event
- DCR: disease control rate
- FDA: US Food and Drug Administration
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer
- ORR: objective response rate
- OS: overall survival
- PD-L1: programmed death-ligand 1
- PFS: progression-free survival

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 13 | Titles free |
| Detailed analysis | 15 sections | Paid |
| Verified statements with short source quotes and links | 109 | Paid |
| Who said each statement: the cited speakers | 26 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 11 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 15 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 18 | Free |
| Sources with links | 43 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 11 of the 26 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

16 discussed · 2 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival (OS) | discussed | 13 | 7 |
| Primary endpoint: Progression free survival (PFS) | discussed | 7 | 6 |
| Secondary endpoint: Objective response rate (ORR) | discussed | 1 | 1 |
| Secondary endpoint: Disease control rate ( DCR) | no commentary found | 0 | 0 |
| Secondary endpoint: Duration of response (DoR) | no commentary found | 0 | 0 |
| Secondary endpoint: Adverse Events (AE): incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results | discussed | 9 | 4 |
| Population and setting | discussed | 9 | 7 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 15 | 10 |
| Safety and tolerability | discussed | 11 | 4 |
| Design and conduct | discussed | 5 | 5 |
| Therapeutic rationale and possible replacement of checkpoint-inhibitor backbones | discussed | 13 | 4 |
| Geographic translation, evidence quality and regulatory expectations | discussed | 16 | 13 |
| Censoring, follow-up and discretionary discontinuation questions | discussed | 4 | 2 |
| ADC alternatives and the case against automatic intensification | discussed | 6 | 3 |
| First-line treatment, later cell-therapy fitness and tissue planning | discussed | 3 | 1 |
| Conditional TIL combination development and a possible selective niche | discussed | 2 | 1 |
| China-specific readiness to use the approach | discussed | 1 | 1 |
| Investment thresholds and cross-application development interpretations | discussed | 10 | 5 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 28 statements · 26%** | | | |
| YouTube | 5 | 1 | 1 |
| Podcasts | 23 | 1 | 1 |
| **Posts · 81 statements · 74%** | | | |
| X threads | 80 | 40 | 61 |
| Bluesky threads | 1 | 1 | 4 |

- Screened window: 2024-09-08 to 2026-11-18
- Cited window: 2024-09-08 to 2026-11-18
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
- Registry: NCT06767514 (https://clinicaltrials.gov/study/NCT06767514)
- Study IDs: SMT112-3007
- Sponsor: Summit Therapeutics
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 780 (estimated)
- Start: 2025-02-27 (actual)
- Primary completion: 2028-04 (estimated)
- Primary endpoint: Overall Survival (OS) (Up to approximately 36 months)
- Primary endpoint: Progression free survival (PFS) (Up to approximately 36 months)
- Intervention: Ivonescimab Injection (biological)
- Intervention: Pembrolizumab Injection (biological)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a question about ivonescimab’s potential clinical role in lung cancer and the need for further trial data.
- 2 passages in 1 source used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 36 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 43 sources about other trials or topics are not included.
- The sources reviewed for this edition do not include a HARMONi-7 protocol or results publication. Statements about enrollment rationale, statistical power and future outcomes are not resolved against those primary documents here.
- No exact product-label source was available for either named injection. Regulatory predictions and safety interpretations are reported as their authors' views, not as an assessment of authorized use.
- The sources chiefly concern explicit HARMONi-7 references. Discussion of the same treatment decision without the trial name, with alternative spellings or in earlier material may be missing.
- Two short passages in one social thread were not fully assessed, and another relevant reply is not represented in the report's statements. Additional questions or qualifications may therefore be missed.
- Comments concern different evidence-disclosure stages. Publication dates alone do not establish presentation or interview dates, subsequent knowledge or changes of mind.
- Public accounts, reported polls and reposts do not provide an independent-HCP denominator, and some public authors' clinical roles are not established. The report cannot establish prevalence, consensus or actual prescribing patterns.
- Several efficacy, safety and regulatory statements concern HARMONi-2, HARMONi-6 or another explicitly distinguished study rather than HARMONi-7. Combination-therapy expectations and tentative comparisons with earlier reports should not be treated as demonstrated monotherapy benefits or safety advantages.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-19 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-19 UTC. No changes.

## Offer

- Size: Focused · 109 verified statements · 41 from 11 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (15 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/harmoni-7-nct06767514
- Agents: POST https://www.erudio.com/api/orders with {"report": "harmoni-7-nct06767514", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=harmoni-7-nct06767514

## Cite

Erudio Health. HARMONi-7 (NCT06767514): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/harmoni-7-nct06767514

## Questions

### How much does the HARMONi-7 report cost?

One edition costs $750 (Focused · 109 verified statements · 41 from 11 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the HARMONi-7 report cover?

109 statements from 43 sources (1 podcast, 1 video, 41 posts), 41 of them from 11 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the HARMONi-7 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "harmoni-7-nct06767514" }) previews it and create_order({ "report": "harmoni-7-nct06767514", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the HARMONi-7 report?

Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/harmoni-7-nct06767514.json
- Markdown: https://www.erudio.com/reports/harmoni-7-nct06767514.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/harmoni-7-nct06767514/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "harmoni-7-nct06767514"}`
